文献速递淋巴瘤造血干细胞移植与细胞治疗

不同移植平台治疗成人T细胞白血病/淋巴瘤的结局比较:突出移植后环磷酰胺单倍体移植

Comparative outcomes of various transplantation platforms, highlighting haploidentical transplants with post-transplantation cyclophosphamide for adult T-cell leukaemia/lymphoma.
PubMed 文献 · Br J Haematol · 2024-10-19

该回顾性研究比较了2016至2021年间700例成人T细胞白血病/淋巴瘤患者接受不同异基因造血干细胞移植平台的结局,包括PTCY单倍体、MRD、MUD和CBT。PTCY组2年OS为48.1%,与MRD和MUD组相近,CBT组为34.6%;PTCY组血小板植入延迟,但严重急慢性GVHD未增加。作者认为PTCY单倍体移植是安全有效的平台。

要点

  • 700例成人T细胞白血病/淋巴瘤患者接受allo-HCT,PTCY组121例、MRD组91例、MUD组160例、CBT组328例。
  • 2年OS:PTCY组48.1%、MRD组48.8%、MUD组48.4%、CBT组34.6%。
  • PTCY组较MRD和MUD组血小板植入延迟,严重急慢性GVHD未增加。

核心结论

  • 作者认为,采用PTCY的异基因造血干细胞移植是成人T细胞白血病/淋巴瘤患者安全有效的平台。

研究设计与样本

  • 回顾性比较不同异基因造血干细胞移植平台结局的研究,纳入2016年至2021年间首次接受allo-HCT的患者。
  • 共纳入700例患者:PTCY组121例、MRD组91例、MUD组160例、CBT组328例。

主要发现

  • 存活者中位随访794天,2年OS为PTCY组48.1%、MRD组48.8%、MUD组48.4%、CBT组34.6%。
  • 2年累积复发率分别为PTCY组37.1%、MRD组47.5%、MUD组33.9%、CBT组45.1%。
  • 2年NRM分别为PTCY组24.2%、MRD组19.8%、MUD组24.7%、CBT组27.3%。
  • PTCY组较MRD和MUD组血小板植入延迟,严重急性或慢性GVHD发生率未增加。
  • PTCY组中体能状态差是OS较差的显著预测因素,输注CD34+细胞数低于5×10⁶/kg与中性粒细胞和血小板植入延迟相关。

关键数值与推荐

  • 原文未报告

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This study retrospectively compared outcomes of various allogeneic haematopoietic cell transplantation (allo-HCT) platforms in patients with adult T-cell leukaemia/lymphoma. Platforms included human leukocyte antigen (HLA)-haploidentical-related donors using post-transplant cyclophosphamide (PTCY), HLA-matched related donors (MRD), HLA-matched unrelated donors (MUD) and cord blood transplantation (CBT). Patients who underwent their first allo-HCT between 2016 and 2021 were included. Outcomes analysed were overall survival (OS), relapse and non-relapse mortality (NRM). Seven hundred patients were included (PTCY, n = 121; MRD, n = 91; MUD, n = 160; CBT, n = 328). With a median follow-up of 794 days for survivors, 2-year OS was 48.1% (PTCY), 48.8% (MRD), 48.4% (MUD) and 34.6% (CBT); the respective 2-year cumulative incidence of relapse was 37.1%, 47.5%, 33.9% and 45.1% and that of NRM was 24.2%, 19.8%, 24.7% and 27.3%. PTCY was associated with delayed platelet engraftment relative to MRD and MUD. There was no increase in the incidence of severe acute or chronic graft-versus-host disease. In the PTCY group, poor performance status was a significant predictor of inferior OS, and infused CD34+ cell numbers of less than 5 × 106/kg were associated with delayed neutrophil and platelet engraftment. These results suggest that allo-HCT with PTCY is a safe and effective platform for patients with adult T-cell leukaemia/lymphoma.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Yoshimitsu M, Tanaka T, Nakano N, et al. Comparative outcomes of various transplantation platforms, highlighting haploidentical transplants with post-transplantation cyclophosphamide for adult T-cell leukaemia/lymphoma. Br J Haematol. 2024. PMID: 39425565. doi:10.1111/bjh.19835

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。